Functional significance of hepatic arterial flow reserve in patients with cirrhosis

Hepatology

Volumn 37, Issue 2, 2003, Pages 385-392

  Zipprich, Alexander ^a   Steudel, Norbert ^a   Behrmann, Curd ^b   Meiss, Frank ^a   Sziegoleit, Ursula ^a   Fleig, Wolfgang E ^a   Kleber, Gerhard ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DEETHYLLIDOCAINE; GALACTOSE; INDOCYANINE GREEN; LIDOCAINE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; DIGITAL SUBTRACTION ANGIOGRAPHY; DOPPLER ECHOGRAPHY; EPIGASTRIC PAIN; FEMALE; FLOW RATE; HUMAN; LIVER CIRCULATION; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PERFUSION; MALE; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PULSATILE FLOW; SCORING SYSTEM; VASODILATATION;

EID: 0037308190     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50065     Document Type: Article

References (42)

1. Morgan DJ, McLean AJ. Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease. HEPATOLOGY 1991;14:1280-1282.
2. Hickey PL, Angus PW, McLean AJ, Morgan DJ. Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. Gastroenterology 1995;108:1504-1509.
3. Froomes PRA, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology 1999;116:915-920.
4. Zipprich A, Steudel N, Meiss F, Balzer C, Fleig WE, Kleber G. Oxygen supplementation improves methacetin clearance in patients with cirrhosis - relation to liver function [Abstract]. Gastroenterology 2001;120(Suppl 1):39.
5. Lautt WW, Legare DJ, Ezzat WR. Quantitation of the hepatic arterial buffer response to graded changes in portal blood flow. Gastroenterology 1990;98:1024-1028.
6. Richter S, Mücke I, Menger MD, Vollmar B. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol 2000;279:G454-G462.
7. Le Couteur DG, Hickey HM, Harvey PJ, Gready J, McLean AJ. Hepatic artery flow and propranolol metabolism in the perfused cirrhotic rat liver. J Pharmacol Exp Ther 1999;289:1553-1558.
8. Mets B, Hickman R, Allin R, Van Dyk J, Lotz Z. Effect of hypoxia on the hepatic metabolism of lidocaine in the isolated perfused pig liver. HEPATOLOGY 1993;17:668-676.
9. Oellerich M, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, Lamesch P, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987;25:845-853.
10. Kleber G, Steudel N, Behrmann C, Zipprich A, Hübner G, Lotterer E, Fleig WE. Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999;116:906-914.
11. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest 1966;18(Suppl 92):118-125.
12. Henderson JM, Kutner MH, Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982;83:1090-1096.
13. Lotterer E, Högel J, Gaus W, Fleig WE, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. HEPATOLOGY 1997;26:1426-1433.
14. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green measurement of hepatic blood flow and a test of hepatic function. Clin Sci 1961;21:43-57.
15. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. HEPATOLOGY 1997;26:1149-1155.
16. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease. HEPATOLOGY 1991;13:787-795.
17. Harvey PJ, Gready JE, Yin Z, Le Couteur DG, McLean AJ. Acute oxygen supplementation restores markers of hepatocyte energy status and hypoxia in cirrhotic rats. J Pharmacol Exp Therapeut 2000;293:641-645.
18. Wakashiro S, Shimahara Y, Ikai I, Tokunaga Y, Ozaki N, Tanaka A, Morimoto T, et al. Influence of hypoxia on mitochondrial function and energy status in CCl4-induced cirrhotic rat liver. Res Exp Med (Berl) 1989;189:153-161.
19. Vachiéry F, Moreau R, Hadengue A, Gadano A, Soupison T, Valla D, Lebrec D. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. J Hepatol 1997;27:492-495.
20. Villeneuve J-P, Dagenais M, Huet P-M, Roy A, Lapointe R, Marleau D. The hepatic microcirculation in the isolated perfused human liver. HEPATOLOGY 1996;23:24-31.
21. Richter S, Vollmar B, Mücke I, Post S, Menger MD. Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers. J Physiol 2001;531:193-201.
22. Ahmad AB, Bennett PN, Rowland M. Influence of route of hepatic administration on drug availability. J Pharmacol Exp Ther 1984;230:718-725.
23. Pang KS, Sherman IA, Schwab AJ, Geng W, Barker R, Dlugoscz JA, Cuerrier G, et al. Role of hepatic artery in the metabolism of phenacetin and acetaminophen: an intravital microscopic and multiple-indicator dilution study in perfused rat liver. HEPATOLOGY 1994;20:672-683.
24. Henrion J, Minette P, Colin L, Schapira M, Delannoy A, Heller FR. Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: a case-controlled, hemodynamic study of 17 consecutive cases. HEPATOLOGY 1999;29:427-433.
25. Evans HM, Zimmerman J, Wilmer JG, Thomas LJ, Ethridge CB. Altered liver function of chronic congestive heart failure. Am J Med 1952;13:704-712.
26. Shorey J, Schenker S, Combes B. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. Am J Physiol 1969;216:1441-1452.
27. Meyer B, Luo H, Bargetzi M, Renner EL, Stalder GA. Quantitation of intrinsic drug metabolizing capacity in human liver biopsy specimens: support for the intact hepatocyte theory. HEPATOLOGY 1991;13:475-481.
28. Huet PM, Villeneuve JP. Determination of drug deposition in patients with cirrhosis. HEPATOLOGY 1983;3:913-918.
29. Le Couteur DG, Hickey HM, Harvey PJ, Gready J, McLean AJ. Hepatic artery flow and propranolol metabolism in the perfused cirrhotic rat liver. J Pharmacol Exp Ther 1999;289:1553-1558.
30. McLean AJ, Le Couteur DG, Heinzow BG, Fleig WE, Kleber G. Hepatic artery flow change and hepatocyte oxygenation in human cirrhosis. Gastroenterology 1999;117:1257-1259.
31. Oellerich M, Burdelski M, Lautz HU, Binder L, Pichtmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. HEPATOLOGY 1991;14:1029-1034.
32. Keiding S, Steiness E. Flow dependence of propranolol elimination in perfused rat liver. J Pharmacol Exp Ther 1984;230:474-477.
33. Schütz E, Shipkova M, Armstrong VW, Oellerich M, Leclerq I, Saliez A, Wallemacq PE, et al. Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans [Letter]. HEPATOLOGY 1998;28:1439-1441.
34. Reichen J. MEGX test in hepatology: the long-sought ultimate quantitative liver function test? J Hepatol 1993;19:4-7.
35. Leclerq I, Saliez A, Wallemacq PE, Horsmans Y, Lambotte L. The monoethylglycinexylidide test does not correctly evaluate lidocaine metabolism after ischemic liver injury in the rat. HEPATOLOGY 1997;26:1182-1188.
36. Huet PM, Lelorier J. Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics. Clin Pharmacol Ther 1980;20:208-215.
37. Oellerich M, Ringe B, Lautz H-U, Schulz M, Schmidt F-W, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990;12:219-226.
38. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. HEPATOLOGY 1995;21:120-128.
39. Angus PW, Mihaly GW, Morgan DJ, Smallwood RA. Oxygen dependence of salbutamol elimination by the isolated perfused rat liver. Biochem Pharmacol 1989;38:1443-1449.
40. Heinzow BJ, Somogyi A, McLean AJ. Influence of hydralazine on the pharmacokinetics or orally administered D-propranolol in conscious dogs. Arch Int Pharmacodyn Ther 1987;286:5-14.
41. Gibson R, McLean AJ, Dudley FJ. The hypotensive effect of nitroglycerine on portal venous pressure in patients with cirrhotic portal hypertension. J Gastroenterol Hepatol 1987;1:201-206.
42. Heinzow BJ, Corbett H, Constantinides S, Bourne R, McLean AJ. Interaction between oral hydralazine and propranolol pharmacokinetics. I. Changes in absorption, presystemic clearance and splanchnic blood flow. J Pharmacol Exp Ther 1984;229:509-515.